In this issue of JAMA Surgery, Jones et al1 provide a detailed accounting of recurrence patterns of pancreatic ductal adenocarcinoma (PDAC) following resection. While not the primary aim of the European Study Group for Pancreatic Cancer (ESPAC)–4 randomized clinical trial,2 recurrence of PDAC was analyzed for 732 patients receiving adjuvant gemcitabine alone or gemcitabine plus capecitabine. Although these agents have essentially become obsolete with the adoption of FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) for treatment of PDAC, the current study manages to provoke many curiosities.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Trudeau M, Vollmer CM. Pancreatic Ductal Adenocarcinoma—ESPAC…or It’s Back? JAMA Surg. Published online September 04, 2019. doi:10.1001/jamasurg.2019.3364
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: